Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Growth Stock: Novo Nordisk vs. Eli Lilly

TheMotleyFool

0 0

Better Growth Stock: Novo Nordisk vs. Eli Lilly: https://g.foolcdn.com/editorial/images/754381/doctor-and-patient-talking.jpg

It's difficult to find a pair of biotech giants that have performed better than Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) this year. Both have left broader equities well behind since 2023 started. It's not a coincidence that these two major players in the diabetes and obesity care market are crushing it. Sales of weight-loss medicines are projected to skyrocket through the end of the decade.

As the two leaders in this field, Novo Nordisk and Eli Lilly are already benefiting. Both stocks seem to have excellent prospects, but which one edges out the other? Let's find out.